Pancreatic Adenocarcinoma Metastatic

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
1
Decitabine 50 MG [Dacogen]Phase 21 trial
Active Trials
NCT05360264TerminatedEst. Oct 2024
Evopoint Biosciences
Evopoint BiosciencesChina - Beijing
1 program
1
XNW27011Phase 1/21 trial
Active Trials
NCT06792435Recruiting240Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Verona PharmaDecitabine 50 MG [Dacogen]
Evopoint BiosciencesXNW27011

Clinical Trials (2)

Total enrollment: 240 patients across 2 trials

NCT05360264Verona PharmaDecitabine 50 MG [Dacogen]

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Start: Jan 2022Est. completion: Oct 2024
Phase 2Terminated

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Start: Jul 2023Est. completion: Dec 2025240 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 240 patients
2 companies competing in this space